Research and Markets: CNS Drug Discoveries Alzheimer's Disease Chapter Predicts the...

Research and Markets: CNS Drug Discoveries Alzheimer's Disease Chapter Predicts the Considerable Changes in the AD Market That May Occur by 2014

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/d4a343/cns_drug_discoveri)
has announced the addition of the "CNS Drug Discoveries: Alzheimer's
Disease Chapter" report to their offering.

This chapter of CNS Drug Discoveries focuses on the Alzheimer's
disease market.

By 2014, there will be considerable change in the Alzheimer's
disease (AD) market due to generic competition, better utilisation of
acetylcholinesterase inhibitors and new product launches which, for
the first time, will treat the condition and not the symptoms.

AD affects approximately 19 million people worldwide, with a
prevalence of approximately 1 per cent in the total population,
although the risk of being afflicted with AD increases with age.

In 2007, approximately US$5.5 billion was spent on the symptomatic
treatment of AD. The vast majority of this revenue was generated by
just four drugs within two main classes, the acetylcholinesterase
inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor
antagonists. However, since all four brands face patent expiration
within the next four to five years, this will have a considerable
impact on the revenues of the companies involved.

Since all currently-available treatments are symptomatic
treatments, aimed at alleviating the symptoms of the disease and
trying to slow the deterioration of the patients, there is a
significant unmet need for improved drugs that can modify the
underlying course of the disease.

There is considerable research being undertaken in this area,
although there have been many casualties including Bellus Health's
Alzhemed (tramiprosate), Axonyx' phenserine and sanofi-aventis'
xaliproden (all discontinued from Phase III trials), and most
recently, the lack of efficacy demonstrated by Myriad
Genetics/Lundbeck's Flurizan (tarenflurbil). The current front runner
is Wyeth/Elan's bapineuzumab, although this too is facing challenges
in development. It may be some time before the first disease-modifying
agents emerge which could revolutionise the way AD is treated.

Key AD questions answered include:

- By what % will the number of AD patients being treated in
developed markets increase annually?

- How are approvals for new indications affecting the sales
potential of Eisai/Pfizer's Aricept?

- What are the characteristics and prospects for Wyeth/Elan's
bapineuzumab?

- What competition could arise for Forest/Lundbeck's
Namenda/Ebixa?

Key Topics Covered:

ALZHEIMER'S DISEASE 1

EXECUTIVE SUMMARY 1

THE FACTS 2

PATIENT STATISTICS 3

PATIENT MODEL 4

DRUG GROWTH DRIVERS 5

DRUG GROWTH RISKS/DAMPENERS 6

THE AD MARKET 7

THE MAJOR PLAYERS 9

PLAYERS AND PRODUCTS IN 2014 10

CURRENT AD TREATMENTS 11

GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E 3

NEW DRUGS IN R&D 32

ANALYSIS OF PHASE III DRUGS 35

GLOBAL SALES FORECASTS OF PHASE III AD DRUGS 20011E - 2014E 41

ANALYSIS OF PHASE II DRUGS 42

COMPETITOR RATIO ANALYSIS 47

DISCONTINUATION OF DRUGS 51

AD APPENDIX 1 52

Products Mentioned:

Key Products Analysed and Forecast:

- Aricept - Pfizer/Eisai

- Bapineuzumab - Elan/Wyeth

- Ebixa/Namenda - Lundbeck/Forest Laboratories

- Exelon - Novartis

- Razadyne - Johnson & Johnson/Shire

For more information visit
http://www.researchandmarkets.com/research/d4a343/cns_drug_discoveri

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com

Copyright Business Wire 2008